4/7
08:00 am
cldi
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
Low
Report
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
4/2
08:09 am
cldi
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 [Yahoo! Finance]
Medium
Report
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 [Yahoo! Finance]
4/2
08:00 am
cldi
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Medium
Report
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
4/1
08:00 am
cldi
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
Low
Report
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
3/31
04:55 am
cldi
Research Suggests the Thymus is Critical in Immunotherapy Outcomes [TheStreet.com]
Low
Report
Research Suggests the Thymus is Critical in Immunotherapy Outcomes [TheStreet.com]
3/29
12:20 am
cldi
Major Discovery Could Reshape Cancer Immunotherapy [TheStreet.com]
High
Report
Major Discovery Could Reshape Cancer Immunotherapy [TheStreet.com]
3/28
09:25 pm
cldi
Calidi Biotherapeutics GAAP EPS of -$5.95 [Seeking Alpha]
High
Report
Calidi Biotherapeutics GAAP EPS of -$5.95 [Seeking Alpha]
3/27
04:25 pm
cldi
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
High
Report
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
3/24
08:10 am
cldi
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials [Yahoo! Finance]
Medium
Report
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials [Yahoo! Finance]
3/24
08:00 am
cldi
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
High
Report
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
3/12
08:00 am
cldi
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
Medium
Report
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
3/9
09:31 pm
cldi
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option [Yahoo! Finance]
Medium
Report
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option [Yahoo! Finance]
3/9
08:50 pm
cldi
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Medium
Report
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
3/6
08:51 am
cldi
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering [Yahoo! Finance]
High
Report
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering [Yahoo! Finance]
3/6
08:30 am
cldi
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
High
Report
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
3/5
05:57 pm
cldi
Calidi Biotherapeutics Announces Proposed Public Offering
High
Report
Calidi Biotherapeutics Announces Proposed Public Offering
2/20
08:00 am
cldi
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
Low
Report
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
2/12
08:00 am
cldi
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
Medium
Report
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
1/28
08:00 am
cldi
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
Low
Report
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026